Brind.

Regulators Review Semaglutide Link to Eye Stroke (NAION)

2 reports, 2 independent Updated Fri 00:00
No new developments lately
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Regulatory bodies, including the European Medicines Agency and the FDA, are reviewing evidence concerning semaglutide and its possible link to NAION, an eye condition described as an "eye stroke". A 2025 analysis published in JAMA Ophthalmology found that people using semaglutide experienced a modest increase in NAION risk compared to those taking SGLT2 inhibitors. Novo Nordisk and Eli Lilly have disputed these allegations. Novo Nordisk stated that company-funded research found no increased risk, while Eli Lilly maintained that current studies do not prove GLP-1 medications cause the condition.

From nypost.com

Why it matters

Some supportBrind's analysis of the reports

The review concerns the safety profile of major GLP-1 drugs used for diabetes and weight management. The findings from the European Medicines Agency and the FDA could impact market authorization and product safety warnings for Novo Nordisk and Eli Lilly.

From nypost.com

Who's involved

  • European Medicines AgencyEuropean regulatory authority reviewing drug safety in the European Union.
  • Novo NordiskPharmaceutical company whose drug, semaglutide, is under safety review.
  • FDAU.S. regulatory agency reviewing drug safety.
  • Eli Lilly and CompanyPharmaceutical company whose drug is also in the GLP-1 class and is disputing the allegations.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Novo NordiskSpeculative

    Novo Nordisk might face changes in sales or costs if regulatory bodies issue market warnings regarding semaglutide.

  • Eli Lilly and CompanySpeculative

    Eli Lilly and Company might see changes in investment or market demand as the safety profile of GLP-1 medications is scrutinized.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped